

Please join us for an AstraZeneca-sponsored, promotional symposium at the 9th ESWI Influenza Conference

On the front line: intranasal vaccine technology in the prevention of childhood influenza

Monday 18 September 2023 | 12:30–13:10 CEST
Auditorium 1, Valencia Conference Centre, Valencia

This symposium explores the key role of mucosal immunity in infection response and how, as an intranasal spray, LAIV has been used in the real-world for the prevention of influenza in children.

12:30–12:45

The first frontier: mucosal immunity and its role in the response to respiratory infections



Peter Openshaw,
CBE, FMedSci
Chairperson
Imperial College London, UK

12:45–13:00

From theory to practice: real-world effectiveness and experience with LAIV



Terho Heikkinen,
MD, PhD
University of Turku, Finland

13:00–13:10

Discussion and Q&A

All

This promotional symposium is organised and funded by AstraZeneca.

The information displayed during the meeting is exclusively to healthcare professionals empowered to prescribe or dispense medicinal products. Please do not distribute in media, supporting materials or communication channels aimed at the general public. La información mostrada durante la reunión está dirigida exclusivamente a Profesionales Sanitarios facultados para prescribir o dispensar medicamentos. Por favor no distribuir en medios, soportes o canales de comunicación dirigidos a público general.

Fluenz Tetra is indicated for the prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. The use of Fluenz Tetra should be based on official recommendations.¹ Profilaxis de la gripe en niños y adolescentes a partir de los 24 meses y menores de 18 años. El uso de Fluenz Tetra debe basarse en recomendaciones oficiales.¹

Prescribing Information can differ from country to country. Please refer to your locally approved label and take this into consideration when viewing this information. UK and Spanish Prescribing Information and EU Summary of Product Characteristics will be available at the meeting. Ficha Técnica disponible en la reunión.

Adverse events should be reported. Healthcare professionals are asked to report any adverse events via their national reporting systems. Adverse events should also be reported to AstraZeneca by visiting <https://contactazmedical.astrazeneca.com>.

LAIV, live attenuated influenza vaccine.

1. European Medicines Agency. Fluenz Summary of Product Characteristics (last accessed: August 2023).

©2023 AstraZeneca Global UK. 1 Francis Crick Avenue, Cambridge, Cambridgeshire CB2 0RE, United Kingdom. All rights reserved.

Vault ID: ES-25057; Date of approval: August 2023.